Title here

Text here

Memorial Sloan-Kettering Cancer Center

AKA Sloan-Kettering Institute for Cancer Research

New York, NY

GuideStar Quick View Everything you need to know...

Memorial Sloan-Kettering Cancer Center

Also Known As:
Sloan-Kettering Institute for Cancer Research
Physical Address:
New York, NY 10021 
EIN:
13-1624182
Web URL:
www.mskcc.org
Leadership:
Dr. Craig B Thompson
Detailed Financial and People Data included in the GuideStar Premium Report Report Added To Cart

Legitimacy Information

  • This organization is registered with the IRS.
  • This organization is required to file an IRS Form 990 or 990-EZ.

Institutional funders should note that an organization’s inclusion on GuideStar.org does not satisfy IRS Rev. Proc. 2011-33 for identifying supporting organizations.

Learn more about GuideStar Charity Check, the only pre-grant due diligence tool that is 100% compliant with IRS Rev. Proc 2011-33.






GuideStar Exchange Member

This organization is a Silver-level GuideStar Exchange participant, demonstrating its commitment to transparency.

Is this your organization's report?
Update your organization's information today!


Basic Organization Information

Memorial Sloan-Kettering Cancer Center

Also Known As:
Sloan-Kettering Institute for Cancer Research
Physical Address:
New York, NY 10021 
EIN:
13-1624182
Web URL:
www.mskcc.org 
NTEE Category:
E Health—General & Rehabilitative 
E24 Hospital (Specialty) 
H Medical Research 
H30 Cancer Research 
Ruling Year:
1962 

Sign in or create an account to see this organization's full address, contact information, and more!


Mission Statement

The mission of Memorial Sloan-Kettering Cancer Center and Affiliated Corporations is to provide leadership in the prevention, treatment and cure of cancer through excellence, vision and cost effectiveness in patient care, outreach programs, research, and education.



Revenue and Expenses

Revenue and Expense data from Forms 990 for 1998 are included in the GuideStar Premium Report. Upgrade Now Report Added To Cart


Balance Sheet

Balance Sheet data from Forms 990 for Year 1998 are included in the GuideStar Premium Report. Upgrade Now Report Added To Cart


Leadership (GuideStar ExchangeThe GuideStar Exchange allows nonprofits to regularly update key information directly to GuideStar. It provides richer and broader information about their programs, impact, finances, people and more. June, 2012)

Dr. Craig B Thompson

Term:

Since Nov 2010

Profile:

Dr. Craig B. Thompson became President and Chief Executive Officer of Memorial Sloan-Kettering Cancer (MSKCC) on November 2, 2010.  He came to MSKCC from the University of Pennsylvania, where he had served since 2006 as Director of the Abramson Cancer Center and Associate Vice President for Cancer Services of the University of Pennsylvania Health System.  Dr. Thompson is a board-certified internist and medical oncologist with extensive research experience in cancer, immunology, and translational medicine. His current research focuses on the role that metabolic changes play in the origin and progression of cancer.  Dr. Thompson is a member of the Institute of Medicine, the National Academy of Sciences, the American Academy of Arts and Sciences, and the Medical Advisory Board of the Howard Hughes Medical Institute.

Leadership Statement:

The Center’s physicians and scientists have pioneered many novel therapeutic regimens that have made possible the remarkable progress in cancer. Its physicians are currently leading more than 500 clinical trials for pediatric and adult cancers. Center pathologists have unsurpassed expertise in using advanced methods to accurately diagnose cancer. Memorial Sloan-Kettering’s surgeons perform more cancer operations than those at any other hospital in the nation, and because their sole focus is cancer, they are highly skilled in the use of surgical techniques that preserve form and function. MSKCC’s radiation oncologists offer leading-edge technologies and techniques in radiation therapy. MSKCC has led the way in understanding cancer and in developing new ways to diagnose and treat it. The Sloan-Kettering Institute (SKI) maintains one of the world’s most dynamic programs of cancer research dedicated to understanding the biology of cancer through programs in cell biology, genetics, biochemistry, molecular biology, structural biology, computational biology, immunology, and therapeutics. SKI’s research staff includes more than 100 laboratory investigators; 450 research fellows, associates, and scholars; and 250 graduate students (both PhD and MD/PhD candidates). In addition, SKI boasts 11 National Academy of Sciences members and seven Howard Hughes Medical Institute investigators. MSKCC scientists and physicians form collaborations that helps speed important research findings from the laboratory to the bedside, in a process known as translational research. Established in 2005, the Human Oncology and Pathogenesis Program (HOPP) is a further effort to increase institutional research strength in areas important in contemporary translational research. HOPP is designed to meld even more thoroughly the cultures of basic biologic science and clinical oncology, augmenting the work conducted in the laboratories of Memorial Sloan-Kettering Cancer Center’s physician-scientists.



Officers for Fiscal Year (IRS Form 990)

Report Added To Cart Officers for 1998 are included in the GuideStar Premium Report. Upgrade Now


Highest Paid Employees & Their Compensation (IRS Form 990)

Highest Paid Employee Data for 1998 are included in the GuideStar Premium Report. Upgrade Now Report Added To Cart


Program: Patient Care

Budget:
$0
Category:
Population Served:
General Public/Unspecified

Program Description:

Founded in 1884, Memorial Sloan-Kettering Cancer Center (MSKCC) is the world’s oldest and largest private cancer center. It has devoted more than a century to patient care and innovative research, making significant contributions to better understand, diagnose, and treat cancer.   MSKCC is one of the nation’s premier cancer centers committed to exceptional patient care, leading-edge research, and unparalleled educational programs. It is one of only 40 institutions in the United States to have been designated Comprehensive Cancer Centers by the National Cancer Institute. The close collaboration between MSKCC physicians and scientists is one of its unique strengths, enabling the Center to provide patients with the best care available today while working to discover more effective strategies to prevent, control, and ultimately cure cancer in the future.   MSKCC has more than 10,000 employees, including 727 hospital attending physicians and 133 Sloan-Kettering Institute member scientists. In 2008, there were 22,689 patients admitted to Memorial Hospital, and 466,884 outpatient visits were accommodated at its Manhattan and regional facilities combined.   MSKCC’s experts have established standards of care and treatment protocols for each type and stage of cancer. Its physicians have an extraordinary depth and breadth of experience in diagnosing and treating all forms of the disease, from the most common to the very rare. Each year, they treat more than 400 different subtypes of cancer. This level of specialization can often have a dramatic effect on patients’ chances for a cure or control of their cancer.   MSKCC offers a full range of programs to help patients and families throughout all phases of treatment, including support groups, genetic counseling, managing cancer pain and symptoms, rehabilitation, integrative medicine services, and assistance in navigating life after treatment.   The Center’s physicians and scientists have pioneered many novel therapeutic regimens that have made possible the remarkable progress in cancer. Its physicians are currently leading more than 500 clinical trials for pediatric and adult cancers. Center pathologists have unsurpassed expertise in using advanced methods to accurately diagnose cancer. Memorial Sloan-Kettering’s surgeons perform more cancer operations than those at any other hospital in the nation, and because their sole focus is cancer, they are highly skilled in the use of surgical techniques that preserve form and function. MSKCC’s radiation oncologists offer leading-edge technologies and techniques in radiation therapy.   MSKCC has led the way in understanding cancer and in developing new ways to diagnose and treat it. The Sloan-Kettering Institute (SKI) maintains one of the world’s most dynamic programs of cancer research dedicated to understanding the biology of cancer through programs in cell biology, genetics, biochemistry, molecular biology, structural biology, computational biology, immunology, and therapeutics. SKI’s research staff includes more than 100 laboratory investigators; 450 research fellows, associates, and scholars; and 250 graduate students (both PhD and MD/PhD candidates). In addition, SKI boasts 11 National Academy of Sciences members and seven Howard Hughes Medical Institute investigators.   MSKCC scientists and physicians form collaborations that helps speed important research findings from the laboratory to the bedside, in a process known as translational research. Established in 2005, the Human Oncology and Pathogenesis Program (HOPP) is a further effort to increase institutional research strength in areas important in contemporary translational research. HOPP is designed to meld even more thoroughly the cultures of basic biologic science and clinical oncology, augmenting the work conducted in the laboratories of Memorial Sloan-Kettering Cancer Center’s physician-scientists.   MSKCC’s training programs prepare the next generation of physicians, scientists, and other healthcare professionals for leadership roles in the life sciences and medicine, especially as related to cancer. The Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences at Memorial Sloan-Kettering was established in 2004. This novel program — which offers a PhD degree in cancer biology — trains gifted young laboratory scientists to work in research areas directly related to cancer and other human diseases.   Expansion   MSKCC has undergone a major expansion, with new construction and renovations designed to meet the growing needs of both its patients and its scientific initiatives. The new Evelyn H. Lauder Breast Center and MSKCC Imaging Center opened in September 2009. This 16-story facility can accommodate an increasing number of breast cancer patients while also expanding services for cancer screening and diagnosis. The Zuckerman Research Center, which opened in 2006, is a leading-edge research facility that houses many cancer research programs in more than 300,000 square feet of laboratory space. Also opened in 2006 was a new 72,000-square-foot surgical center that includes 21 state-of-the-art operating rooms, all of which are equipped for both minimally invasive and traditional open surgery. MSKCC has also developed a network of community-based, state-of-the-art outpatient cancer treatment facilities that bring the Center’s expert care closer to patients living throughout its geographical area.     :   The Institution’s primary catchment area encompasses 28 counties in Long Island, southern New York State, northern New Jersey, southwestern Connecticut, and the five boroughs of New York City. Additionally, over 10,000 patients from other parts of the United States and 1,000 international patients were treated in 2008, representing approximately ten percent of the Institution’s patients.

Program Long-Term Success:

LEADERSHIP and HONORS: -In 2002, Memorial Hospital welcomed Physician-in-Chief, Robert E. Wittes, and, the Sloan-Kettering Institute welcomed Thomas J. Kelly, both prominent physician-researchers who are working to ensure that the number and quality of multidisciplinary projects focused on cancer continue to grow and flourish. -The Developmental Biology Program within SKI was created. Kathryn V. Anderson, head of the Laboratory of Developmental Genetics, was elected to the National Academy of Sciences. -The Albert Lasker Award for Basic Research (aka: "America's Nobels") was presented to James E. Rothman, an investigator at MSKCC since 1991. Dr. Rothman was recognized for his discoveries relating to cellular trafficking, which underlies many crucial functions in the body. -The National Cancer Institute (NCI) further endorsed Memorial Sloan-Kettering as a national resource for scientific discovery and cancer care through a 55% increase in funding of the MSKCC's Cancer Center Support Grant. FACILITY EXPANSION: -MSKCC opened its first freestanding outpatient facility in Commack, Long Island. The 50,000 square-foot Suffolk Outpatient Center offers a wide range of services including cancer diagnosis, chemotherapy, radiation therapy, and surgical consultations, as well as cancer screening. -The Sidney Kimmel Center for Prostate and Urologic Cancers opened to patients in March 2002. This center provides multidisciplinary care under one roof, offering patients convenience and facilitating research collaborations that will advance the standard of care for prostate and genitourinary cancers. EDUCATION: -Over 1,200 residents and clinical fellows completed MSKCC's surgical oncology training program. CLINICAL TRIALS: -Close to 13,000 MSKCC patients (more than 20%) were enrolled in research protocols.

Program Short-Term Success:

Program Success Monitored by:

Program Success Examples:


Impact Summary from the Nonprofit

MSKCC has more than 10,000 employees, including 727 hospital attending physicians and 133 Sloan-Kettering Institute member scientists.   In 2008, there were 22,689 patients admitted to Memorial Hospital, and 466,884 outpatient visits were accommodated at its Manhattan and regional facilities combined. To meet the growing needs of both its patients and its scientific initiatives, MSKCC has undergone a major expansion, with new construction and renovations designed. The new Evelyn H. Lauder Breast Center and MSKCC Imaging Center opened in September 2009. This 16-story facility can accommodate an increasing number of breast cancer patients while also expanding services for cancer screening and diagnosis. The Zuckerman Research Center, which opened in 2006, is a leading-edge research facility that houses many cancer research programs in more than 300,000 square feet of laboratory space. Also opened in 2006 was a new 72,000-square-foot surgical center that includes 21 state-of-the-art operating rooms, all of which are equipped for both minimally invasive and traditional open surgery. MSKCC has also developed a network of community-based, state-of-the-art outpatient cancer treatment facilities that bring the Center’s expert care closer to patients living throughout its geographical area.

Organization Data Available

Adobe PDF Format A GuideStar Premium Report in PDF format is available for this organization

Price for this Report: $125.00

This Premium Report includes:

  • Financial Data for
  • Financial Charts for
  • Forms 990 for
  • Forms 990T for
  • Audited Financial Statement for
  • Annual Reports for
  • Letter of Determination
  • Form 1023 / 1024
  • Board Members
  • Officer, Director and/or Highest Paid Employee data for


Learn more about GuideStar Premium